Anavex Life Sciences to Present at the 13th International Conference on Alzheimer's and Parkinson's Diseases AD/PD™ 2017
March 29 2017 - 8:00AM
Anavex Life Sciences Corp. (“Anavex” or the
“Company”) (Nasdaq:AVXL), a clinical-stage
biopharmaceutical company developing differentiated therapeutics
for the treatment of neurodegenerative and neurodevelopmental
diseases including Alzheimer’s disease, other central nervous
system (CNS) diseases, pain and various types of cancer, announced
today data presentations related to Anavex’s Alzheimer’s disease
pipeline as well as Christopher U. Missling, PhD, President and
Chief Executive Officer, participating on a panel at the 13th
International Conference on Alzheimer's and Parkinson's Diseases.
The conference takes place from March 29 to April 2, 2017, in
Vienna, Austria.
Panel Title: AD/PD™ 2017 FORUM ON TRANSLATIONAL
RESEARCH IN DRUG DISCOVERY FOR AD: A PLETHORA OF TARGETS: WHICH IS
THE BEST, IS THERE "A BEST ONE"? Date/Time: Thursday, March 30;
2:45 p.m. - 4:45 p.m. CETLocation: HALL A
Oral Presentation Title: TARGETING M1 MUSCARINIC
AND SIGMA-1 RECEPTORS IN ALZHEIMER'S DISEASE: REVERSAL OF
PATHOLOGICAL HALLMARKS AND ASSOCIATED COGNITIVE DYSFUNCTION IN
MCGILL-R-THY1-APP RATS (Data related to ANAVEX 3-71)Date/Time:
Thursday, March 30; 7.00 p.m. - 7.15 p.m. CETLocation: HALL A
Poster Presentation Title: THE DUAL REGULATION
OF OXIDATIVE STRESS BY SIGMA1 RECEPTORS IN PHYSIOLOGICAL OR
PATHOLOGICAL CONDITIONS (Data related to ANAVEX 2-73, ANAVEX 3-71,
ANAVEX 1-41)Date/Time: Saturday, April 1; 8.00 a.m. - 6.00 p.m.
CETLocation: Poster Number 007
Data will be available on the Anavex website www.anavex.com
concurrently with the respective sessions.
About Anavex Life Sciences
Corp.
Anavex Life Sciences Corp. (Nasdaq:AVXL) is a
publicly traded biopharmaceutical company dedicated to the
development of differentiated therapeutics for the treatment of
neurodegenerative and neurodevelopmental diseases including
Alzheimer’s disease, other central nervous system (CNS) diseases,
pain and various types of cancer. Anavex’s lead drug candidate,
ANAVEX 2-73, recently successfully completed a Phase 2a clinical
trial for Alzheimer’s disease. ANAVEX 2-73 is an orally available
drug candidate that restores cellular homeostasis by targeting
sigma-1 and muscarinic receptors and successfully completed Phase
1. Preclinical studies demonstrated its potential to halt and/or
reverse the course of Alzheimer’s disease. It has also exhibited
anticonvulsant, anti-amnesic, neuroprotective and anti-depressant
properties in animal models, indicating its potential to treat
additional CNS disorders, including epilepsy and others. The
Michael J. Fox Foundation for Parkinson’s Research has awarded
Anavex a research grant to develop ANAVEX 2-73 for the treatment of
Parkinson’s disease to fully fund a preclinical study, which could
justify moving ANAVEX 2-73 into a Parkinson’s disease clinical
trial. ANAVEX 3-71, also targeting sigma-1 and M1 muscarinic
receptors, is a promising preclinical drug candidate demonstrating
disease modifications against the major Alzheimer’s hallmarks in
transgenic (3xTg-AD) mice, including cognitive deficits, amyloid
and tau pathologies, and also with beneficial effects on
neuroinflammation and mitochondrial dysfunctions. Further
information is available at www.anavex.com. You can also connect
with the company on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks set forth in the Company’s most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and Anavex Life
Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date
hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors:
Matthew Haines
River East Investor Relations, LLC
917-733-9297
mhaines@rivereastir.com
Media:
Dennis Dobson, Jr.
Dobson Media Group
203-258-0159
dennisdobsonjr@dobsonmediagroup.com
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Sep 2023 to Sep 2024